Form 4: Mirum Pharmaceuticals Director Equity Grant

Director Michael G. Grey received an equity grant of stock options and restricted stock units from Mirum Pharmaceuticals.

Summary

• Director Michael G. Grey was granted 3,772 stock options with an exercise price of $101.
• Director Michael G. Grey was granted 1,980 restricted stock units (RSUs).
• Both the stock options and RSUs vest on the first anniversary of the grant date (June 15, 2027), or upon the date of the 2027 annual stockholder meeting, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The issuance of new equity results in minor dilution to existing shareholders.

Risks

• Market volatility could impact the value of the granted equity instruments.
• Failure to meet performance or retention milestones could affect the ultimate value realized by the director.

Future Outlook

The equity grants are subject to standard vesting schedules tied to the 2027 annual stockholder meeting, indicating a focus on director retention through the next fiscal year.

Management Comments

• The grants are contingent rights to receive common stock, subject to vesting conditions.

Industry Context

StockSavvy.ai notes that standard equity compensation for board members in the biotechnology sector is a common practice to ensure alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of a mix of stock options and RSUs is consistent with standard executive and director compensation packages in the mid-cap pharmaceutical industry.
• Vesting schedules tied to annual meetings are standard corporate governance practice for non-employee directors.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity instruments.

Next Steps

• Vesting of equity grants on the earlier of the first anniversary or the 2027 annual stockholder meeting.

Key Dates

Keywords

MIRM, Mirum Pharmaceuticals, Form 4, Director Compensation, Equity Grant, Insider Transaction